Bibliographie collaborative AIH – Juillet 2015


Proposé par Nicolas Gendron et Clémence Roux, supervisé par David Smadja

  1. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 20 août 2015;373(8):697‑704.
  1. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 27 août 2015;373(9):823‑33.
  1. Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 10 sept 2015;373(11):1032‑9.
  1. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 6 août 2015;373(6):511‑20.
  1. Gerrits AJ, Leven EA, Frelinger AL, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 10 sept 2015;126(11):1367‑78.
  1. Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 27 août 2015;126(9):1078‑85.
  1. Søgaard KK, Farkas DK, Pedersen L, et al. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood. 20 août 2015;126(8):957‑63.
  1. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 1 sept 2015;ehv466.
  1. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 10 sept 2015;373(11):997‑1009.
  1. Cung T-T, Morel O, Cayla G, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med. 10 sept 2015;373(11):1021‑31.

Leucémies aiguës

Proposé par Lucile Debus et Ludovic Gabellier, supervisé par Pierre Hirsch

  1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52.
  1. Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. 2015 Aug;29(8):1637-47.
  1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015 Nov 1;33(31):3641-9.
  1. Ali S, Jones GL, Culligan DJ, et al. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 2015 Aug;170(4):487-95.
  1. Qin H, Cho M, Haso W, et al. nEradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein. Blood. 2015 Jul 30;126(5):629-39.
  1. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. 2015 Aug 6;126(6):746-56.
  1. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. 2015 Jul 16;126(3):291-9.
  1. Cho BS, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. 2015 Jul 9;126(2):222-32.
  1. Ocio EM1, Herrera P2, Olave MT3, et al. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II Panobidara study. 2015 Oct;100(10):1294-300.
  1. Lebon D, Vergez F, Bertoli S, et al. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leuk Res. 2015 Aug;39(8):818-21.

Allogreffe de cellules souches hématopoïétiques

Proposé par Zoé Van de Wyngaert et Dinh Ngoc Mai, supervisé par Régis Peffault de Latour

  1. Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 1;33(28):3152-61.
  1. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8.
  1. Robin M, Porcher R, Adès L, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015 Jul;29(7):1496-501.
  1. Francesca Fioredda, Simona Iacobelli, Anja van Biezen, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation, Blood 2015 Oct 15;126(16):1885-92. 

Syndromes myéloprolifératifs

Proposé par Lin-Pierre Zhao et Yola Dakdouki, supervisé par Jean Christophe Lanotto

1.     Baerlocher GM1, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 3;373(10):920-8.

2.     Deininger M, Radich J, Burn TC, et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015 Sep 24;126(13):1551

3.     Burchert A, Saussele S, Eigendorff E, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015 Jun;29(6):1331-5.

4.     Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 6;126(6):790-7.

5.     Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015 Jul 2;126(1):42-9.

Hémopathie bénigne

Proposé par Milena Kohn et Vincent Allain, supervisé par Louis Terriou

  1. Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). 2015 Jul 23;126(4):500-3.
  1. Michel M, Suzan F, Adoue D, et al. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. Br J Haematol. 2015 Jul;170(2):218-22.
  1. Frelinger AL 3rd, Grace RF, Gerrits AJ, et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. 2015 Aug 13;126(7):873-9.
  1. Malinowski AK, Shehata N, D’Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015 Nov 19;126(21):2424-35; quiz 2437.
  1. Mankelow TJ, Griffiths RE, Trompeter S, et al. Autophagic vesicles on mature human reticulocytes explain phosphatidylserine-positive red cells in sickle cell disease. 2015 Oct 8;126(15):1831-4.
  1. Mettananda S, Gibbons RJ, Higgs DR. α-Globin as a molecular target in the treatment of β-thalassemia.Blood. 2015 Jun 11;125(24):3694-701.
  1. Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015 Aug;15(8):500-10.
  1. Alkhairy OK, Perez-Becker R, Driessen GJ, et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 J Allergy Clin Immunol. 2015 Sep;136(3):703-712.
  1. Hosokawa K, Muranski P, Feng X, et al. Identification of novel microRNA signatures linked to acquired aplastic anemia. 2015 Dec;100(12):1534-45.
  1. Grangé S, Bekri S, Artaud-Macari E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet. 2015 Sep 5;386(9997):1011-2.


Proposé par Cédric Rossi et Camille Bigenwald, supervisé par Fabrice Jardin

  1. Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. 2015 Jul 16;126(3):328-35.
  1. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol. 2015 Sep 10;33(26):2857-62.
  1. Wang W, Hu S, Lu X, et al. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements Clinicopathologic Features of 11 Cases. Am J Surg Pathol. 2015 Aug;39(8):1132-9.
  1. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015 Sep 1;61(5):719-29.
  1. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015 Jul;170(2):179-84. 


Proposé par Alexis Talbot et Floriane Theves, supervisé par Laurent Frenzel

  1. Usmani SZ, Rodriguez-Otero P, Bhutani M, et al. Defining and treating high-risk multiple myeloma. 2015 Nov;29(11):2119-25.
  1. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol.2015 Sep 10;33(26):2863-9.
  1. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
  1. Rajkumar SV, Landgren O, Mateos MV. Smolderingmultiple myeloma. 2015 May 14;125(20):3069-75.
  1. Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone(CPD) in patients with relapsed and/or refractory multiple myeloma. 2015 Nov 12;126(20):2284-90.
  1. Karadimitris A , Chaidos A, Caputo V, et al. Myeloma propagating cells, drug resistance and relapse. Stem Cells.2015 Nov;33(11):3205-11.

Leucémie lymphoïde chronique

Proposé par Claire Bréal et Florian Chevillon, supervisé par Loic Ysebaert 

  1. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139.
  1. McCarthy BA, Yancopoulos S, Tipping M, et al. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B Lymphocytes. Immunol Res. 2015 Dec;63(1-3):90-100.
  1. Brown JR, Davids MS, Rodon J, et al. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/ Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15;21(14):3160-9.
  1. Caroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Sep 28:1-7.
  1. Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. 2015 Sep;29(9):1811-22.